ViaCyte and CRISPR Therapeutics announced a strategic collaboration to modify ViaCyte’s stem cell-based therapy to reduce or eliminate the need for immunosuppression. Below, FENIX provides insight on the collaboration including context from the CRISPR patent dispute.